Crestor/ABT-335 combination: Phase III started

The companies began the 12-week, double-blind, U.S. Phase III M06-844 trial in 675 patients with Type IIa or IIb dyslipidemia to evaluate Crestor/ABT-335 combination or ABT-335 and Crestor as monother...